Source: Imugene
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Imugene (IMU) has completed the Phase 1a monotherapy dose escalation of PD1-Vaxx and will now go on to the combination dose escalation
  • The PD1-Vaxx is a B-cell activating immunotherapy designed to treat tumours such as lung cancer
  • The trial was performed by using 10, 50 and 100 micrograms of PD1-Vaxx in non-small cell lung cancer patients
  • Imugene will now add combination therapy of PD1-Vaxx to the Phase 1b portion of the clinical trial
  • Shares have been up 6.88 per cent trading at 42.8 cents

Imugene (IMU) has completed the Phase 1a monotherapy dose escalation of PD1-Vaxx and will now go on to the combination dose escalation.

The ongoing Phase I data represents a clinical proof-of-concept for PD1-Vaxx monotherapy with early efficacy signals.

Imugene’s PD1-Vaxx is a B-cell activating immunotherapy designed to treat tumours such as lung cancer by interfering with PD-1/PD-L1 binding and interaction, producing an anti-cancer effect similar to Tecentiq, Keytruda, Opdivo, and other immune checkpoint inhibitor monoclonal antibodies.

The trial was performed by using 10, 50 and 100 micrograms of PD1-Vaxx in non-small cell lung cancer patients which can produce an anti-cancer effect.

The company says the trials are designed to look for safety, tolerability and early response signals, to determine the optimal dose for further development.

Imugene will now add combination therapy of PD1-Vaxx in the phase 1b portion of the clincal trial. This next stage of studies will involve previously untreated patients with non-small cell lung cancer patients.

The company said plans are now being finalised to combine PD1-Vaxx with Roche/Genentech’s PD-L1 targeting blockbuster immune checkpoint inhibitor, atezolizumab.

In other company news, Imugene has appointed two former employees of Roche/Genentech to its senior management team.

Ursula McCurry has been appointed Senior Vice President of Clinical Operations and has over 20 years of global clinical development experience. In another appointment, Nimali Withana will take on the role of Senior Director of Clinical Science. Dr Withana has over 18 years of drug development experience.

Shares in Imugene were up 6.88 per cent trading at 42.8 cents at 11.17 am AEDT.

IMU by the numbers
More From The Market Online
The Market Online Video

Market Close: Green lights up on ASX for Easter hunt go

The ASX200 closed the day in record territory - nearly a per cent up with every…

Week 13 Wrap: Easter bunny delivers new all time high for ASX200

Another week, another all time high. The ASX200 clocked 7,901pts on Thursday for the first time…

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Market Update: ASX glows red hot with another hit record

The ASX200 is trading up, hitting a new high of 7901 point and eclipsing the last…